Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals

被引:27
|
作者
An, Panpan [1 ]
Li, Jiexin [1 ]
Lu, Linlin [1 ]
Wu, Yingmin [1 ]
Ling, Yuyi [1 ]
Du, Jun [1 ]
Chen, Zhuojia [2 ]
Wang, Hongsheng [1 ]
机构
[1] Sun Yat Sen Univ, Sch Pharmaceut Sci, Dept Microbial & Biochem Pharm, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
TNBC; Migration; HDAC8; YAP; TRANSCRIPTION; HDAC8; PROTEIN;
D O I
10.1016/j.ejphar.2018.12.030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Triple-negative breast cancer (TNBC) shows highly aggressive clinical behaviors and poor prognosis compared to other breast cancer subtypes. Histone deacetylases (HDACs) can regulate the progression of various cancers, but the role of HDAC8 in TNBC remains unexplored. Here, we found that HDAC8 enhanced the in vitro migration abilities of breast cancer cells. Targeted inhibition of HDAC8 via si-HDAC8 and its selective inhibitor PCI34051 could suppress the migration of cells. In TNBC cells, HDAC8 stabilized the expression and increased the nuclear localization of YAP, a major downstream effector of Hippo pathway. While silencing YAP could attenuate HDAC8 triggered migration of TNBC cells. Mechanistically, HDAC8 suppressed the phosphorylation of YAP(ser127), which was related to its cytoplasmic sequestration degradation. Our data revealed that HDAC8 could trigger the migration of TNBC cells via regulation of Hippo-YAP signals, suggesting that HDAC8 might be a potential target for TNBC therapy.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 50 条
  • [41] Additive pharmacological interaction between histone deacetylase inhibitors and cisplatin in triple negative breast cancer cells with altered NOTCH1 activity
    Wawruszak, Anna
    Luszczki, Jarogniew
    Kalafut, Joanna
    Okla, Karolina
    Halasa, Marta
    Rivero-Mueller, Adolfo
    Avery-Kiejda, Kelly
    Stepulak, Andrzej
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 46 - 46
  • [42] The migration of metastatic breast cancer cells is regulated by matrix stiffness via YAP signalling
    Chen, Wei
    Park, Shihyun
    Patel, Chrishma
    Bai, Yuxin
    Henary, Karim
    Raha, Arjun
    Mohammadi, Saeed
    You, Lidan
    Geng, Fei
    HELIYON, 2021, 7 (02)
  • [43] RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis
    Zhongbo Li
    Peng Su
    Yinlu Ding
    Honglei Gao
    Huijie Yang
    Xin Li
    Xiao Yang
    Yan Xia
    Chenmiao Zhang
    Mingxi Fu
    Dehai Wang
    Ye Zhang
    Shu Zhuo
    Jian Zhu
    Ting Zhuang
    Cell Communication and Signaling, 20
  • [44] DLAT promotes triple-negative breast cancer progression via YAP1 activation
    Liu, Diya
    Wang, Xuehui
    Qian, Fengyuan
    Ye, Danrong
    Deng, Xiaochong
    Fang, Lin
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [45] RBCK1 is an endogenous inhibitor for triple negative breast cancer via hippo/YAP axis
    Li, Zhongbo
    Su, Peng
    Ding, Yinlu
    Gao, Honglei
    Yang, Huijie
    Li, Xin
    Yang, Xiao
    Xia, Yan
    Zhang, Chenmiao
    Fu, Mingxi
    Wang, Dehai
    Zhang, Ye
    Zhuo, Shu
    Zhu, Jian
    Zhuang, Ting
    CELL COMMUNICATION AND SIGNALING, 2022, 20 (01)
  • [46] Cynaropicrin, a sesquiterpene lactone, triggers apoptotic cell death in triple negative breast cancer cells
    Hjazi, Ahmed
    Alissa, Mohammed
    Alqasem, Abdullah A.
    Alghamdi, Abdullah
    Alghamdi, Suad A.
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [47] Extracellular secreted Ref-1 triggers triple negative breast cancer cells apoptosis
    Lee, Yu Ran
    Kim, Ki Mo
    Joo, Hee Kyoung
    HwaJeon, Byeong
    Choi, Sunga
    CANCER RESEARCH, 2015, 75
  • [48] Histone deacetylase inhibitors as differentiation agents in breast cancer cells
    Ismail, H.
    Bail, M.
    Laperriere, D.
    Mader, S.
    FEBS JOURNAL, 2014, 281 : 303 - 303
  • [49] Troglitazone inhibits histone deacetylase activity in breast cancer cells
    Davies, G. F.
    Ross, A. R.
    Arnason, T. G.
    Juurlink, B. H. J.
    Harkness, T. A. A.
    CANCER LETTERS, 2010, 288 (02) : 236 - 250
  • [50] Histone deacetylase inhibitor panobinostat in combination with rapamycin confers enhanced efficacy against triple-negative breast cancer
    Wu, Kunlin
    Zhang, Huihao
    Zhou, Linlin
    Chen, Ling
    Mo, Caiqin
    Xu, Sunwang
    Lin, Junyu
    Kong, Lingjun
    Chen, Xiangjin
    EXPERIMENTAL CELL RESEARCH, 2022, 421 (01)